- Home
- XFOR vs NTHI Comparison
XFOR vs NTHI Comparison
Compare XFOR & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- NTHI
- Stock Information
- Founded
- XFOR 2014
- NTHI 2008
- Country
- XFOR United States
- NTHI United States
- Employees
- XFOR N/A
- NTHI N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- XFOR Health Care
- NTHI Health Care
- Exchange
- XFOR Nasdaq
- NTHI Nasdaq
- Market Cap
- XFOR 118.4M
- NTHI 142.5M
- IPO Year
- XFOR N/A
- NTHI N/A
- Fundamental
- Price
- XFOR $3.40
- NTHI $7.24
- Analyst Decision
- XFOR Strong Buy
- NTHI
- Analyst Count
- XFOR 3
- NTHI 0
- Target Price
- XFOR $72.33
- NTHI N/A
- AVG Volume (30 Days)
- XFOR 180.2K
- NTHI 108.1K
- Earning Date
- XFOR 05-01-2025
- NTHI 01-01-0001
- Dividend Yield
- XFOR N/A
- NTHI N/A
- EPS Growth
- XFOR N/A
- NTHI N/A
- EPS
- XFOR 2.16
- NTHI N/A
- Revenue
- XFOR $31,364,000.00
- NTHI $79,990.00
- Revenue This Year
- XFOR $915.88
- NTHI N/A
- Revenue Next Year
- XFOR N/A
- NTHI N/A
- P/E Ratio
- XFOR $1.57
- NTHI N/A
- Revenue Growth
- XFOR N/A
- NTHI 13.52
- 52 Week Low
- XFOR $2.67
- NTHI $4.11
- 52 Week High
- XFOR $33.90
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- XFOR 39.83
- NTHI N/A
- Support Level
- XFOR $2.67
- NTHI N/A
- Resistance Level
- XFOR $3.56
- NTHI N/A
- Average True Range (ATR)
- XFOR 0.28
- NTHI 0.00
- MACD
- XFOR 0.21
- NTHI 0.00
- Stochastic Oscillator
- XFOR 82.02
- NTHI 0.00
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").